Plasticity-related gene-1 (PRG-1) protects neuronal cells from lysophosphatidic acid (LPA) effects. In vascular smooth muscle cells (VSMCs), LPA was shown to induce phenotypic modulation in vitro and vascular remodeling in vivo. Thus we explored the role of PRG-1 in modulating VSMC response to LPA. PCR, Western blot, and immunofluorescence experiments showed that PRG-1 is expressed in rat and human vascular media. PRG-1 expression was strongly inhibited in proliferating compared with quiescent VSMCs both in vitro and in vivo (medial vs. neointimal VSMCs), suggesting that PRG-1 expression is dependent on the cell phenotype. In vitro, adenovirus-mediated overexpression of PRG-1 specifically inhibited LPA-induced rat VSMC proliferation and migration but not platelet-derived growth factor-induced proliferation. This effect was abolished by mutation of a conserved histidine in the lipid phosphate phosphatase family that is essential for interaction with lipid phosphates. In vivo, balloon-induced neointimal formation in rat carotid was significantly decreased in vessels infected with PRG-1 adenovirus compared with ␤-galactosidase adenovirus (Ϫ71%; P Ͻ 0.05). PRG-1 overexpression abolished the activation of the p42/p44 signaling pathway in LPA-stimulated rat VSMCs in culture and in balloon-injured rat carotids. Taken together, these findings provide the first evidence of a protective role of PRG-1 in the vascular media under pathophysiological conditions. lysophosphatidate; lipid phosphate phosphatase; phenotypic modulation; neointimal formation; MAPK VASCULAR SMOOTH MUSCLE CELLS (VSMCs) are known to be one of the cell types that exist along a continuum of phenotypes. A differentiated phenotype with a contractile function is predominant in mature arteries, whereas a phenotypic modulation (22), characterized by a switch towards a synthetic profile, occurs in vascular injury conditions such as atherosclerosis or restenosis following percutaneous transluminal angioplasty.
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Lysophosphatidic acid (LPA), a potent bioactive glycerophospholipid, plays an important role in VSMCs dedifferentiation characterized in vitro by proliferation and migration (13, 31) and in vivo by neointima formation (39) . LPA concentration in the serum results from a balance between its synthesis by autotaxin and/or A-type phospholipase (2) , at least in part after platelet activation, and degradation by the lipid phosphate phosphatases (LPPs; Ref. 6 ). In a global way, LPA is considered as a pathophysiological mediator of vascular cell function involved in many cardiovascular diseases such as atherothrombosis (25, 28) and hypertension (36) . Several studies contributed to shed light on the mechanisms underlying the effects of LPA. In the VSMCs, it binds to specific G-protein-coupled receptors, LPA1 to LPA4 (13, 18) , activating many downstream pathways involving signaling proteins such as RhoA and Erk1/2 (1, 18, 23) and transcription factors such as response element binding protein and serum response factor leading to Egr-1 expression (8) , which promotes expression of genes implicated in vascular diseases (3) .
Here, we focused on studying the role of plasticity-related gene-1 (PRG-1)/lipid phosphate phosphatase-related protein-4 (LPPR-4), a new member of the LPP superfamily, described for the first time in the brain (4, 5) . PRG-1 is a calmodulinbinding protein (30) and was shown to protect against LPAinduced axon collapse and neuron hyperexcitability by LPA dephosphorylation and by LPA internalization (5, 33) . In previous microarray studies on media of rat thoracic aorta, we observed a downregulation of PRG-1 expression in conditions of vascular remodeling in vivo, i.e., during N G -nitro-L-arginine-methyl ester (L-NAME)-induced hypertension (9) .
We hypothesized that PRG-1 expression in vascular media might regulate LPA effects on VSMCs. In this study, we have examined PRG-1 expression in the vessel wall and the effect of PRG-1 overexpression on VSMC function in vitro and neointima formation in vivo.
MATERIALS AND METHODS

Rat and human vascular tissue and cell isolation surgery. Male
Wistar rats (CERJ, Orléans, France) were treated in accordance with our institutional guidelines (Ministère de l'Agriculture, France; authorization 75-1206) and conformed to the Directive 2010/63/EU of the European Parliament. Rat VSMCs were isolated from the media of the thoracic aorta and cultured as previously described (35) . Rat lymphocytes were isolated from 3 ml of rat blood using the FicollHypaque protocole (GE Healthcare, Saclay, France). Rat carotid artery injury, adenoviral infection, death, and tissue collection and were performed as previously described (19) . Rats were anesthetized with pentobarbital sodium (50 mg/kg, 1 ip injection) and anesthesia was monitored by periodic observation of respiration and pain response. After surgery, the animals received Meloxicam (1.5 mg/kg, 1 sc injection) and Furosemide (5 mg/kg ip). To retrieve carotid artery or aorta, rats were killed by pentobarbital overdose (150 mg/kg ip) followed by removal of the heart. Rat aortic media were prepared as already described (9) . All surgical procedures were approved (Ministère de l'Agriculture, France, authorization for surgery C-75-665-R). Human aortas and coronary arteries were obtained from heart transplant (Surgical Department of the Cardiology, Institute at Pitié-Salpêtrière Hospital, Paris, France) in accordance with French ethical laws (L.1211-3-9) and with the principles outlined in the Declaration of Helsinki.
Adenovirus production and control. Plasmid pEGFP-N1-hPRG1 was kindly provided by R. Nitsch (Berlin, Germany). The adenovirus expressing human PRG-1 (Ad-hPRG1) and the control expressing ␤-galactosidase (Ad-LacZ) were generated using ADeasy system (Clontech, Ozyme, Saint Quentin en Yvelines, France). Ad-hPRG1-H252K was generated by mutation of the conserved catalytic histidine (His252) with lysine by site-specific mutagenesis (Quikchange sitedirected mutagenesis kit; Agilent Technologies, Massy, France). Purification and titration were performed with Clontech kits. Ad-LacZinfected VSMCs [3.10 7 infectious units (ifu) for 10 6 cells] were X-Gal stained after 72 h of infection and showed an infection efficiency of nearly 100%. Human PRG-1 overexpression in rat VSMCs was confirmed by PCR, Western blot, and immunofluorescence analysis (Fig. 1, A-C) .
X-Gal staining. After 3 days of adenoviral infection, rat VSMCs were fixed with formaldehyde 2% (Sigma-Aldrich, Lyon, France) for 5 min at 4°C. Fixed cells were incubated in staining solution [PBS with 10 mmol/l K3Fe(CN)6, 10 mmol/l K4Fe(CN)6, 2 mmol/l MgCl2, and 1 mg/ml X-Gal; all reagents were purchased from Sigma-Aldrich] from 1 h to overnight at 37°C.
PCR expression measurements. DNA from injured rat carotids was extracted according to the manufacturer's instructions (Kit Gentra systems; Qiagen, Courtaboeuf, France). PCR on genomic DNA was performed using 200 ng of DNA, 1 U of BIOTAQ DNA polymerase (Bioline), and 5 pmol of each primer. Primer sequences were as follows: adenovirus, sense 5=-TCTCAAACATGTCTGCGGGT-3= and antisense 5=-TTCAGGTGTTTATGTGTTTT-3=; rat, Id3 sense 5=-AGCCGCTTAGCCTCTTGGA-3= and antisense 5=-TCGTAC-CTGGATCGGGAGAT-3=.
Total RNA was extracted from rat brain, rat aortic media, human total aorta, rat VSMCs, and rat lymphocytes/monocytes using RNeasy (Qiagen) according to the manufacturer's protocol. Total RNA from rat VSMCs not infected, infected with Ad-LacZ, and infected with Ad-hPRG-1 was extracted using the MirVana kit (Ambion, Applied Biosystems, Courtaboeuf, France) and treated with DNase I (Ambion) according to the manufacturer's protocol. RNA (500 ng) was reverse transcribed and real-time PCR was performed on a Mx4000 apparatus (Stratagene) using SYBR Green I Ready Taq Master Mix (Sigma) as already described (9) . For normal PCR, cDNA (1/20 th ) was amplified for 25 cycles (Rpl32), 40 cycles (rat PRG-1), or 30 cycle (human PRG-1) using 1 U of BIOTAQ DNA polymerase (Bioline, Abcys, Les Ulis, France) and 5 pmol of each primer.
Primer sequences were as follows: rat, PRG-1 sense 5=-AAGT-CATTCCCGTCCCAGC-3= and antisense 5=-GCGCGATTCCTCCTC-CAAT-3=; rat Rpl32, sense 5=-CCAGAGGCATCGACAACA-3=and antisense 5=-GCACTTCCAGCTCCTTGACAT-3=; human PRG-1, sense 5=-ACAACAGCATGCCTGGAGGGCCAAGAGTGT-3= and antisense 5=-TTATAGCGGATGGAGCCAGTG-3=; rat ␣-smooth muscle actin (SMA), sense 5=-CCCTCTTCCAGCCATCTTTCATT-3= and antisense 5=-TGGTAGTGCCCCCCGAGA-3=; rat ␥-SMA, sense 5=-ACAGAG-GCCCCCCTAAACC-3= and antisense 5=-GTGACGCCATCCCCT-GAAT-3=; rat SM22, sense 5=-ATGCAGTGTGGCCCTGATGT-3= and antisense 5=-AGGCTGTTCACCAACTTGCTC-3=.
PRG-1 immunodetection. Total proteins were extracted from tissues or cells in denaturing WCE1 buffer (8.3 mol/l M urea, 2 mol/l thiourea, 4% CHAPS, 1% dithiothreitol, and 24 mmol/l spermine base). Lysates were incubated on rotation during 30 min and then centrifuged at 18,000 g for 30 min. All steps were performed at room temperature. Concentration of proteins in the supernatants was assayed with Bradford reagent (Bio-Rad, Marnes-la-Coquette, France). Proteins (60 g) were loaded with CB2X buffer (1 mol/l Tris·HCl pH 6.8, 20% SDS, 87% glycerol, 2% dithiothreitol, and 5% Coomassie brilliant blue G-250) and separated by SDS-PAGE; blotted on PVDF membrane; labeled with anti-PRG-1, kindly provided by R. Nitsch (5), and anti-cyclin D1 (no. 556470; BD Biosciences); and revealed using ECL plus reagent (GE Healthcare).
Histology and immunofluorescence studies. Tissues were frozen in OCT embedding (Cell Path, Mid-Wales, UK), and 8-m cryosections were performed. Media thickness was measured on hematoxylin and eosin-stained frozen cross sections with a computer-based morphometric system (Lucia; Nikon, Tokyo, Japan). Ten measurements were made on each section, and five discontinuous sections were analyzed in each animal.
For immunofluorescence analysis, sections were fixed in PFA 3% for 15 min at room temperature, permeabilized 10 min in cold acetone and blocked in DakoCytomation antibody diluent (Dako, Trappes, France) with 5% goat serum (Sigma-Aldrich), and all antibodies were diluted in Dako-1.5% goat serum. Cells were fixed in PFA 4% for 15 min at room temperature, permeabilized in 0.1% saponin (Calbiochem, Merck, Martillac, France), and blocked in PBS-BSA 5% (Sigma-Aldrich), and antibodies were diluted in PBS-BSA 1%. Primary antibodies used were anti-PRG-1 n°PRG-147 (peptide sequence H 2N-CLSKRRNGVGLEP-CONH2, generated by Eurogentec, Angers, France), anti-PRG-1 (5), anti-nonmuscle myosin (Ab 684; Abcam), anti-SM-2 (Ab 683; Abcam), and anti-Ki-67 (Ab 15580; Abcam). Visualization was performed by applying secondary antibodies directly conjugated to Alexa Fluor 488, 594, or 633 (Life Technologies, Saint Aubin, France) and DAPI staining of nuclei. The specificity of antibody anti-PRG-1 n°PRG-147 was confirmed by immunofluorescence studies on cells infected with Ad-LacZ or with AdhPRG1 adenoviruses (Fig. 1C) . All photos were taken using confocal microscope Leica SP2 AOBS AOTF and analyzed with Leica Confocal Software.
Proliferation assay by bromodeoxyuridine incorporation. Rat VSMCs were cultured in 96-well tissue culture plates for 3 days after infection with 3.10 7 ifu/10 6 cells of adenoviruses Ad-LacZ and Ad-hPRG1. Cells were growth arrested for 3 days (0% FCS) and incubated for 24 h with bromodeoxyuridine (BrdU) and stimulated with either 10% FCS, 4 mol/L LPA (Sigma-Aldrich), or platelet-derived growth factor (PDGF; 10 ng/ml; R&D Systems, Lille, France). Proliferation was measured after 24 h with a chemiluminescent BrdU immunoassay according to the manufacturer's instructions (Roche Applied Science). VSMC proliferation was also assayed in presence of 40 ng/ml PD98059 (Sigma-Aldrich) during 20 min before stimulation with LPA or FCS.
Wound migration assay. Twelve-well tissue culture plates were coated with 50 g/ml collagen-type II (Sigma-Aldrich) and rat VSMCs were cultured for 3 days after adenovirus infection. Cells were starved in medium with 0% FCS during 3 days. Cell proliferation was blocked by incubation (2 h) with 20 mol/l mitomycin C (Sigma-Aldrich). Confluent cell monolayer was wounded by scrapping with a 200-l pipette tip and was incubated with starving medium 4 mol/l ϮLPA. The distance of wound closure was photographed and measured over a 24-h period, using MetaMorph software.
Measurement of p42/44 activity. Rat VSMCs were cultured for 3 days after adenovirus infection in 12-well tissue culture plates. Cells were starved in medium with 0% FCS during 3 days and then
Coomassie staining
Anti-PRG-1 Immunoblot stimulated with LPA 5 mol/l during 5 min. Cells were then scrapped in Laemmli buffer 4ϫ, denatured at 95°C (5 min). Noninjured and injured carotid protein extracts were prepared in RIPA buffer (150 mM NaCl, 50 mM Tris·HCl pH 7.5, 2% deoxycholic acid, 0.2% SDS, and 2% Triton X-100) with protease and phosphatase inhibitors (Sigma) using a polytron homogenizer. Proteins (10 g for VSMC extracts and 15 g for carotid extracts) were separated by SDS-PAGE, blotted on PVDF membrane (Perkin Elmer), and incubated with anti-phospho-p42/44 and p42/44 (Cell Signaling, Ozyme). Immunoreactive proteins were visualized by using an ECL plus detection system (GE Healthcare), scanned with an Ettan DIGE Imager (GE Healthcare), and quantified using ImageQuant (GE Healthcare). Apoptosis assay. Rat VSMCs were cultured for 3 days after adenoviruses infection in six-well tissue culture plates. Apoptosis was assayed using the Cell Death Detection ELISA according to the manufacturer's instructions (Roche Applied Science, Meylan, France).
Statistics analysis. Values are expressed as means Ϯ SD. Statistical analysis was performed using a nonparametric Mann and Whitney test for single comparisons. Multiple comparisons were analyzed using one-way ANOVA followed by Student-Newman-Keuls post hoc test with XLSTAT software (Addinsoft, Paris, France). P values Ͻ 0.05 were considered to be significant.
RESULTS
PRG-1 is expressed in human and rat VSMCs.
We first detected PRG-1 vascular expression by studying aortic media gene modulation during L-NAME-induced hypertension in rat (9) . PRG-1 was present on the DNA chip as an unknown EST and was identified by Blast analysis (probeset rc_AI228462_at). PRG-1 expression in the aorta was downregulated during L-NAMEinduced hypertension (ϫ0.31 and ϫ0.55, respectively, after 15 and 30 days of L-NAME treatment compared with control rats). We therefore sought to confirm PRG-1 expression in vascular cells. PRG-1 expression in the vascular bed was determined by PCR, immunoblot, and immunofluorescence. PRG-1 mRNA was detected in the media of rat thoracic aorta whereas it was not detectable in rat VSMC primary culture (Fig. 1D) . Total RNA from rat brain and from rat circulating lymphocytes was used as positive and negative controls, respectively.
At the protein level, PRG-1 expression was analyzed by Western blot (Fig. 1E) . The protein was detected as a band of 82 kDa present in rat hippocampus protein extract and at lower levels in rat aortic media protein extract. We then examined PRG-1 localization in the vascular wall by immunofluorescence. In rat aorta, PRG-1 expression was localized in the medial SMCs between the elastin layers (Fig. 1F) . PRG-1 mRNA and protein were also detected in human aorta (data not shown).
Taken together, these results show the presence of PRG-1 in rat and human vascular tissue and suggest a downregulation of its expression in conditions of dedifferentiation and proliferation such as primary cultured VSMCs.
PRG-1 expression is downregulated in proliferating arterial VSMCs in vitro and in vivo.
These first results and our microarray data obtained in hypertensive rats indicated that PRG-1 expression was regulated in conditions of vascular remodeling and of VSMC phenotypic modulation. We compared PRG-1 expression in proliferating (10% FCS) and quiescent (serum starvation) VSMCs by RT-PCR. In quiescent VSMCs, PRG-1 mRNA expression was present whereas it was not detectable in proliferating VSMCs (Fig. 2A) . This upregulation of PRG-1 expression in serum-deprived cells was confirmed at the protein level by Western blot (Fig. 2B ). Quiescence was confirmed by downregulation of cyclin D1 expression, a marker of proliferating VSMCs (Fig. 2B) , and by the upregulation of differentiation markers such as ␣-SMA, ␥-SMA, and SM22 (7, 40) whose upregulated expression was confirmed by real-time PCR (Fig. 2C) .
In vivo, PRG-1 expression was analyzed by immunofluorescence in the vessel wall of rat and human arteries with neointimal proliferation. The model of balloon-injured carotid arteries was studied in the rat. Proliferating neointimal cells, characterized by a strong nonmuscle myosin staining, showed a lower PRG-1 expression compared with the quiescent VSMCs of the media, where we observed a strong PRG-1 signal and a light NM-B staining (Fig. 2D) . Similar observations were obtained in samples from various patients where PRG-1 staining was barely detectable in the neointima of human coronary arteries (Fig. 2E ) and of aortas (data not shown), whereas a strong signal was shown in medial SMCs. We characterized quiescent SMCs by a SM-2-positive staining, a phenotypic marker of SMCs (Fig. 2E) . These results confirm in vivo the downregulation of PRG-1 expression in conditions of VSMCs proliferation and dedifferentiation.
Overexpression of PRG-1 inhibits VSMCs proliferation and migration in vitro but has no effect on apoptosis. LPA was shown to induce VSMC migration and proliferation (31) . This prompted us to study the role of PRG-1 on VSMC function. As its expression was strongly diminished in primary cultured rat VSMCs, we overexpressed PRG-1 by adenoviral infection. The role of PRG-1 on VSMC proliferation was measured using BrdU incorporation in rat VSMCs stimulated by LPA, FCS, or PDGF (Fig. 3A) . We studied the effects of overexpression of wild-type PRG-1 (Ad-hPRG1) and of PRG-1 mutated on the conserved catalytic histidine His252 (Ad-hPRG1-H252K), which is essential for interaction with lipid phosphates. Mutation of this histidine completely abolished the function of PRG-1 (5, 33) and of LPP-1 (42) . Both forms of PRG-1 were similarly expressed in Ad-hPRG1-or Ad-hPRG1-H252K-infected HeLa cells (Fig. 3B) . Basal proliferation levels in serumfree medium were similar among noninfected, Ad-LacZ-, AdhPRG1-, and AdhPRG1-H252K-infected cells (100 Ϯ 13, 108 Ϯ 13, 104 Ϯ 12, and 107 Ϯ 13, respectively; NS). Within 24 h, addition of 4 mol/l LPA, 10 ng/ml PDGF, or 10% FCS significantly induced proliferation both in noninfected VSMC (165 Ϯ 14, 178 Ϯ 7, and 200 Ϯ 9, respectively; P Ͻ 0.01 vs. untreated control) and in Ad-LacZ-infected cells (159 Ϯ 10, 177 Ϯ 6, and 198 Ϯ 13, respectively; P Ͻ 0.01 vs. untreated control). Human PRG-1 overexpression significantly decreased LPA and serum-induced proliferation (130 Ϯ 9 and 163 Ϯ 15, respectively; P Ͻ 0.01 vs. Ad-LacZ-infected cells) but had no effect on PDGF-induced proliferation (176 Ϯ 8; NS vs. AdLacZ-infected cells). Mutation of histidine 252 completely abolished PRG-1 effect on LPA and FCS-induced proliferation (169 Ϯ 18 and 203 Ϯ 17, respectively; P Ͻ 0.01 vs. noninfected or Ad-LacZ-and Ad-hPRG1-H525K-infected cells with similar treatments). We did not observe any difference in VSMC apoptosis in Ad-hPRG1-and Ad-hPRG1-H525K-infected cells compared with Ad-LacZ-infected cells under serum deprivation (Fig. 3C) . However, less apoptosis was observed in noninfected cells, indicating some apoptosis due to the infection itself. These results show that PRG-1 overexpression inhibits LPA-induced VSMC proliferation in vitro. This effect is specific of LPA as it is not observed with PDGF, another growth factor, and is dependent on a functional LPA recognition domain.
PRG-1 effect on VSMCs migration was studied using the scrape-wound assay (Fig. 4, A and B) . To exclude any cell growth effect, cells were beforehand starved in 0% FCS medium for 3 days and incubated with mitomycin C for 2 h. In the absence of serum, some basal migration was observed probably due to the autocrine and paracrine secretion of several molecules inducing migration such as PDGF. Neither Ad-LacZ nor Ad-hPRG1 infection significantly modified basal cell migration in serum-free medium. As expected, addition of 4 mol/l LPA during 24 h to serum-free medium induced a significant increase in cell migration in control noninfected 
. PRG-1 expression is downregulated in proliferating VSMCs in vitro and in vivo.
A: PRG-1 mRNA was detected by RT-PCR in serum-starved cultured rVSMCs but was completely absent in cells exposed to 10% FCS for 72 h. Rpl32 amplification was used as a control for PCR loading. Figure represents 3 independent experiments. B: representative Western blot of PRG-1 protein expression in the same conditions as described in A. Cyclin D1 was used as a marker of proliferation and ␤-actin as a loading control. C: VSMC differentiation genes ␣-smooth muscle actin (␣-SMA), transgelin (SM22), and ␥-smooth muscle actin (␥-SMA) mRNA levels were quantified by real-time PCR in the same samples as in A and normalized to Rpl32 expression levels. Induction is expressed compared with the value obtained in 10% FCS. Values are means Ϯ SD of 3 independent experiments. *P Ͻ 0.05 0% FCS vs. 10% FCS. D: representative sections of balloon-injured rat carotid arteries 14 days after injury colabeled with anti-PRG-1 and anti-nonmuscle myosin (anti-NM-B). Immunostaining revealed PRG-1 expression (red) predominantly in the media (m) and a weak expression in the neointima (n.i.). Expression of PRG-1 inversely correlated with that of NM-B (grey), a phenotypic marker of VSMCs proliferation. E: immunolabeling of human coronary artery presenting neointimal formation. In the media, PRG-1 labeling correlates with SM-2 labeling, a phenotypic marker of quiescent VSMCs whereas in the neointima both staining are much weaker.
VSMCs (195 Ϯ 40 vs. 108 Ϯ 34 pixels; P Ͻ 0.001) and in Ad-LacZ-infected VSMCs (188 Ϯ 27 vs. 97 Ϯ 32 pixels; P Ͻ 0.001). However, LPA-induced VSMC migration in AdhPRG1-infected VSMCs was greatly reduced when compared with LPA-treated Ad-LacZ-infected VSMCs (105 Ϯ 26 pixels; P Ͻ 0.001) and did not significantly differ from basal migration of Ad-hPRG1-infected VSMC (74 Ϯ 24 pixels; NS). These data indicate that LPA-induced VSMC migration in vitro is inhibited by PRG-1 overexpression.
Adenoviral overexpression of PRG-1 prevents angioplastyinduced neointima formation in vivo.
We explored in vivo the effect of adenoviral-induced PRG-1 expression on VSMC proliferation in the balloon angioplasty-associated restenosis model. After carotid injury, human PRG-1 expression was induced by gene transfer using adenoviral infection (3.10 10 ifu). Two weeks after injury and infection, rats were killed and cross sections of injured carotids were stained with hematoxylin-eosin. Adenovirus infection of injured vessels was confirmed by PCR on DNA of injured and infected carotid arteries (Fig. 5A) . We performed morphometric analysis to measure the neointima and media thickness in ballooned carotid arteries infected with Ad-LacZ and Ad-hPRG1 and to calculate intima/ media (I/M) thickness ratios (Fig. 5, B and C) . Carotid injury resulted in a marked neointimal formation in the control Ad-LacZ group compared with noninjured right carotids. This ratio was significantly lower (Ϫ71%; P Ͻ 0.05) in Ad-hPRG-1-infected arteries (0.38 Ϯ 0.26; n ϭ 6) than in Ad-LacZ infected arteries (1.39 Ϯ 0.93; n ϭ 6). In parallel, immunodetection of Ki-67-positive cells in balloon-injured carotid arteries shows a decrease in the number of proliferative VSMCs in the neointima of animals infected with Ad-hPRG1 compared with Ad-LacZ (Fig. 5D ). These data show that hPRG-1 adenoviral expression inhibited in vivo neointima formation and VSMC proliferation after balloon injury.
PRG-1 overexpression blocks LPA-induced p42/44 phosphorylation in vitro and in vivo.
To further explore the role of PRG-1 in controlling LPA stimulation of VSMC, we studied the p42/44 kinase pathway, one of the signaling pathways induced by LPA in VSMC (18) . We first verified whether LPA-induced proliferation was dependent on this downstream signaling pathway. Serum-depleted cells were preincubated with PD98059, an inhibitor of p42/44 activation, and then stimulated for 24 h with either LPA at 4 mol/l or FCS at 10% in the presence of BrdU to assay their proliferation. As shown in Fig. 6A , PD98059 preincubation did not modify basal proliferation (88 Ϯ 3 vs. 100% in serum-free condition; NS). LPA-and serum-induced proliferations (162 Ϯ 21 and 292 Ϯ 42%, respectively; P Ͻ 0.01) were significantly inhibited by PD98059 treatment (124 Ϯ 14 and 231 Ϯ 37%, respectively; P Ͻ 0.01 vs. conditions without PD98059). Thus LPA-and serum-induced VSMC proliferations are in part dependent on p42/44 signaling pathway activation. We therefore determined the effect of hPRG-1 expression on LPAinduced p42/44 activation measured by p42/44 phosphorylation. Serum-depleted cells were stimulated for 5 min with 5 mol/l LPA, and p42/44 phosphorylation was determined by Western blot analysis (Fig. 6B ) and normalized to p42/44 levels (Fig. 6B') . At basal state, the ratio of phospho p42/44 to total p42/44 was not significantly different between noninfected cells, Ad-LacZ-and Ad-hPRG1-infected cells (1, 0.9 Ϯ 0.1, and 0.7 Ϯ 0.2, respectively; NS). Under LPA stimulation, the p42/44 phosphorylation was significantly induced in noninfected cells and Ad-LacZ-infected cells (1.7 Ϯ 0.1 and 1.4 Ϯ 0.2, respectively; P Ͻ 0.05 vs. serum-free condition) but not in Ad-PRG-1-infected cells (0.5 Ϯ 0.1; P Ͻ 0.05 vs. Ad-LacZinfected cells). In vivo, p42/44 phosphorylation (Fig. 6 , C and C') was also significantly increased in Ad-LacZ-infected carotid arteries 2 days after balloon injury compared with noninjured right carotid arteries (ϫ2.6 Ϯ 0.8; P Ͻ 0.05). This activation of p42/44 was totally abolished in balloon-injured carotid arteries infected with Ad-hPRG1 (ϫ1.2 Ϯ 0.1; P Ͻ 0.05 vs. Ad-LacZ). These results show that PRG-1 inhibits LPA-induced p42/44 signaling pathway in VSMC in vitro and in vivo and that LPA-induced VSMC proliferation partly depends on activation of this pathway.
DISCUSSION
In this study, we demonstrate for the first time that PRG-1 is expressed and plays a protective and antiproliferative role in VSMCs. We show that PRG-1 expression is downregulated during phenotypic modulation of VSMC and that restoration of PRG-1 expression inhibits LPA-induced VSMC proliferation and migration in vitro, prevents neointimal formation in vivo and downregulates LPA-induced p42/p44 activation. Altogether, these data show that PRG-1 is a new modulator of the effects of LPA on VSMC function.
Unsaturated LPA has been shown to induce VSMC phenotypic modulation characterized by modification of the cell shape, decreased expression of SMC differentiation marker genes (13), intracellular calcium mobilization (38) , stimulation of DNA synthesis, and SMC proliferation (16, 36) . These effects depend on several signaling pathways such as RhoA, p42/p44 and p38MAPK. The p42/p44 signaling pathway is a major mediator of VSMC stimulation by LPA (13, 23, 37) and also an important mediator of VSMC phenotypic modulation as inhibition of this pathway maintains VSMC in a differentiated phenotype (13) . Our in vitro and in vivo data suggest that PRG-1 helps preventing VSMC phenotypic modulation through inhibition of LPA-induced proliferation, migration, and p42/44 activation. This inhibition was specific of LPA as it was not observed with another inducer of VSMC proliferation such as PDGF. Moreover, PRG-1 also partially prevented seruminduced VSMC proliferation. This result is in agreement with previous results suggesting that LPA is an important component of the proliferative and migratory activity of serum (23) .
There is growing in vivo evidence for an important role of LPA in the vessel neointima formation. Carotid ligation in- duces the vascular expression of autotaxin, the LPA-producing enzyme, and of the LPA receptors LPA 1 and LPA 2 , altogether probably leading to an enhanced LPA signaling pathway (23) . In addition, injection of LPA induces neointimal formation in rat (39, 41) and inhibition of LPA receptors, either pharmacologically or by knockdown, protects against neointimal outgrowth in mice (23, 29) . Our results add new in vivo evidence for a deleterious role of LPA in inducing VSMC proliferation and migration in injured vessels. Firstly, restoration of PRG-1 expression in injured vessels protected to a great extent against neointimal outgrowth. Secondly, neointimal cells express lower levels of PRG-1 than medial cells, consistent with an inhibitory effect of PRG-1 on LPA-induced VSMC proliferation and migration. Moreover, we and others have detected p42/p44 activation in rat carotid artery after balloon angioplasty (14) and neointima formation is dependent on p42/p44 activation (12, 15, 39) . Thus our in vitro and in vivo data suggest that PRG-1 protects against neointimal formation by inhibiting VSMC proliferation and migration and by preventing Erk1/2 activation in the vessel wall.
It will be important to decipher the mechanisms underlying PRG-1 inhibition of LPA effects. In agreement with previous studies (21, 30), we were not able to detect PRG-1 phosphatase activity in the extracellular medium (data not shown). This result is also not in favor of an increased LPA dephosphorylation or uptake in PRG-1 expressing VSMC, as it was demonstrated in neurons (33) . However, mutation of a histidine crucial for LPP activity and interaction with lipid phosphates completely abolished PRG-1 effects confirming previous observations that PRG-1 activity is dependent on its involvement in lipid phosphate signaling (5, 33, 42) . PRG-1 may prevent the interaction of LPA with its receptors by sequestering LPA in a similar way to FrzA, which binds Wnt and blocks Wnt-induced VSMC proliferation (11) . Additionally, PRG-1 could interact with receptors or signaling proteins in particular through the large COOH terminus intra-cytoplasmic tail of PRG-1, which is not present in other LPPs (5). Indeed PRG-1 was suggested to function as a receptor for LPA because it lacks some of the conserved important residues of the catalytic motif, which confers the phosphatase activity to LPPs (27) . Thus PRG-1 effects may not depend on a reduced availability of extracellular LPA but on the regulation of intracellular pathways such as PKC or phospholipase D2 activities as observed with LPP1 in fibroblasts (20, 24) .
VSMCs express other members of the LPP family that dephosphorylate LPA. Analysis of our own DNA chip data (9) and of other microarray data deposited in the GEO repository reveals that LPP1, LPP2, and LPP3, the three classical LPA phosphatases, are expressed in VSMC, but we did not observe any regulation of their expression during L-NAME-induced hypertension. These LPPs, in particular LPP1, also inhibit LPA-induced cell migration and proliferation through inhibition of p42/p44 activation (20, 24) and could play a role in vascular remodeling. However, evidence for such a role is lacking although gene knockout studies have revealed an important role for LPP3 and not LPP1 in vascular development (10, 32) . Our data demonstrate here the regulation and protective role of PRG-1, a nonclassical LPP, during vascular remodeling.
Our results suggest that PRG-1 could constitute an interesting and powerful therapeutic approach against neointimal outgrowth and maybe other vascular diseases. However, the balloon angioplasty on rat carotid artery injury is a model with limitations that does not represent all the mechanisms involved in human restenosis. It involves healthy vessel from young animals in a species that does not undergo atherosclerosis whereas human neointimal formation is mostly found in aged and/or atherosclerotic vessels. Nevertheless, PRG-1 could modulate the abnormal proliferation and migration of VSMCs associated with other vascular pathologies in particular in atherosclerosis. Indeed, recent data showed that LPA might be involved in atheroma development as it is a component of minimally oxidized LDL (13) and as high concentrations of LPA were found associated with atherosclerotic plaques (26) .
In conclusion, we provide the first evidence that PRG-1 is expressed in VSMCs and is an important regulator of VSMC proliferation and migration in vivo and in vitro. We demonstrated that PRG-1 inhibits LPA-induced signaling, preventing activation of p42/p44, one of the major signaling pathways of VSMC phenotypic modulation. PRG-1 is one of many genes responding to the dedifferentiation program that is set on during phenotypic modulation and allows cell response to proliferative signals and, as such, can be regarded as a phenotypic marker of VSMCs. Further studies will allow confirming if PRG-1 expression and regulation involves important regulatory mechanisms previously identified in VSMCs such as CArG boxes or chromatin modifications (17) .
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